ArticlebioRxiv : the preprint server for biology2025
Loss of CFIm activates YAP/TAZ and connects mRNA cleavage and polyadenylation inhibition to BRCAness.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The YAP/TAZ transcription program plays a crucial role in development, regeneration, and cancer. CFIm is a master regulator of mRNA alternative polyadenylation (APA). Loss of CFIm function was shown in human cancer but its impact on the gene expression program is not well characterized. Here we report the discovery that loss of CFIm in cancer cells activates YAP/TAZ and promotes therapeutic resistance. We identified a CFIm-NEDD4L-LATS1 regulatory axis that suppressed YAP/TAZ activation. Furthermore, we found that CFIm loss in the presence of mRNA cleavage and polyadenylation (CPA) inhibition repressed key DNA repair genes in the Fanconi anemia (FA) and homology-directed repair (HDR) pathways, which induced the BRCAness phenotype and aggravated DNA damage. Our study reveals a hidden link between mRNA 3' end processing and the YAP/TAZ transcription program in addition to illustrating how CFIm function impacts the selection of therapeutic agents in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.